| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/04/2006 | EP1612210A1 New analogs of nitrobenzylthioinosine |
| 01/04/2006 | EP1612208A2 N-phenylarylsulfonamide compound, pharmaceutical composition comprising the compound as active ingredient, synthetic intermediate for the compound and process for its preparation |
| 01/04/2006 | EP1612206A1 Anti-obesity agent |
| 01/04/2006 | EP1612204A1 Hydrazone derivative |
| 01/04/2006 | EP1612203A1 Crystalline forms of (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride |
| 01/04/2006 | EP1611902A1 Preventive and/or therapeutic agent for neuropathic pain |
| 01/04/2006 | EP1611901A1 Preventive or remedy for teeth grinding |
| 01/04/2006 | EP1611900A1 Method of treating inflammtory disease associated with bone destruction |
| 01/04/2006 | EP1611896A1 Use of n-acetyl-d-aminoglycosamine in treatment of local lesions or systematic symptoms related to autoimmune reactions |
| 01/04/2006 | EP1611895A1 Use of n-acetyl-d-aminoglycosamine in treatment of organ lesions related to toxicosis of drugs or chemicals |
| 01/04/2006 | EP1611894A1 Use of n-acetyl-d-aminoglycosamine in treatment of non-specific inflammations related to physical or chemical factors |
| 01/04/2006 | EP1611893A1 Remedy for nerve damage |
| 01/04/2006 | EP1611892A2 Pharmaceutical compositions comprising drospirenone |
| 01/04/2006 | EP1611891A2 Use of (2-imidazolin-2-ylamino) quinoxalines in treating ocular neural injury |
| 01/04/2006 | EP1611890A1 Methods for assessing and treating cancer |
| 01/04/2006 | EP1611889A1 Antibacterial agent and anticancer agent |
| 01/04/2006 | EP1611888A1 Antitussives |
| 01/04/2006 | EP1611887A2 Modulation of peroxisome proliferator-activated receptors |
| 01/04/2006 | EP1611886A2 Inhibitors of the renin-angiotensin system for the prevention of cardiovascular disorders |
| 01/04/2006 | EP1611885A1 Use of an inducing agent for the treatment of blood, viral and cellular disorders |
| 01/04/2006 | EP1611884A1 Patch containing nonsteroidal antiinflammatory and analgesic agent |
| 01/04/2006 | EP1611883A1 Composition for ophthalmic use |
| 01/04/2006 | EP1611881A1 Pregelatinized starch in a controlled release formulation |
| 01/04/2006 | EP1611880A2 Pharmaceutical formulations for the safe administration of drugs used in the treatment of drug addiction |
| 01/04/2006 | EP1611414A2 Method and apparatus for system management using codebook correlation with symptom exclusion |
| 01/04/2006 | EP1611248A1 Diagnostic method for glaucoma |
| 01/04/2006 | EP1611231A2 Rna interference compositions and methods |
| 01/04/2006 | EP1611161A1 Method to produce a solid form of heparin |
| 01/04/2006 | EP1611147A1 6"-amino-6"-deoxygalactosylceramides |
| 01/04/2006 | EP1611144A1 Derivatives of 2-(8,9-dioxo-2,6-diazabicyclo(5.2.0)non-1(7)-en-2-yl)alkyl phosphonic acid and their use as n-methyl-d-aspartate (nmda) recetor antagonists |
| 01/04/2006 | EP1611139A1 Methods of preparing olanzapine |
| 01/04/2006 | EP1611138A1 A novel crystalline form of dorzolamide hydrochloride |
| 01/04/2006 | EP1611137A1 Salts of tricyclic inhibitors of poly(adp-ribose) polymerases |
| 01/04/2006 | EP1611131A1 Pyrazolopyridine derivates |
| 01/04/2006 | EP1611130A2 Reverse-turn mimetics and method relating thereto |
| 01/04/2006 | EP1611123A2 Tie-2 modulators and methods of use |
| 01/04/2006 | EP1611122A1 Substituted pyrazole compounds |
| 01/04/2006 | EP1611120A1 Novel methods for the treatment of inflammatory diseases |
| 01/04/2006 | EP1611119A1 Pi-3 kinase inhibitor prodrugs |
| 01/04/2006 | EP1611116A2 Calcium channel inhibitors comprising benzhydril spaced from piperazine |
| 01/04/2006 | EP1611115A1 Benzothiazole derivative compounds, compositions and uses |
| 01/04/2006 | EP1611111A2 Process for resolving 2,4-diamino-3,6-dihydro-1,3,5-triazines, useful for the treatment of disorders associated with insulin resistance syndrome |
| 01/04/2006 | EP1611097A1 Indole derivatives useful for the treatment of deseases |
| 01/04/2006 | EP1611096A2 Benzamide modulators of metabotropic glutamate receptors |
| 01/04/2006 | EP1611095A2 A method of providing a steroid-sparing benefit with a cyclooxygenase-2 inhibitor and compositions therewith |
| 01/04/2006 | EP1611094A1 Pyrazole compounds |
| 01/04/2006 | EP1611091A1 Novel compounds |
| 01/04/2006 | EP1611088A2 Hydroxamates as therapeutic agents |
| 01/04/2006 | EP1610810A2 Use of clusterin for the treatment and/or prevention of peripheral neurological diseases |
| 01/04/2006 | EP1610806A2 Method of treating cancer with azaspirane compositions |
| 01/04/2006 | EP1610800A2 Methods and compositions for increasing the anaerobic working capacity in tissues |
| 01/04/2006 | EP1610799A1 Compositions comprising hyaluronic acid for the prevention of urogenital infections |
| 01/04/2006 | EP1610798A2 Estradiol metabolites for the treatment of pulmonary hypertension |
| 01/04/2006 | EP1610797A1 Antiviral combination of nevirapine and a further antiretroviral compound |
| 01/04/2006 | EP1610796A2 High potency dopaminergic treatment of neurological impairment associated with brain injury |
| 01/04/2006 | EP1610795A2 Heterocyclic substituted 1,4-dihydro-4-oxo-1,8-naphthpyridine analogs |
| 01/04/2006 | EP1610794A1 A method of treating liver disease |
| 01/04/2006 | EP1610793A2 Thiazoles useful as inhibitors of protein kinases |
| 01/04/2006 | EP1610792A1 Calcium channel blockers comprising two benzhydril moieties |
| 01/04/2006 | EP1610791A1 Implantable polymeric device for sustained release of dopamine agonist |
| 01/04/2006 | EP1610790A2 Anticancer compounds |
| 01/04/2006 | EP1610788A1 Synergistic combination comprising roflumilast and an anticholinergic agent selected from ipratropium, oxitropium and tiotropium salts for the treatment of respiratory diseases |
| 01/04/2006 | EP1610785A2 Pharmaceutical combination for the treatment of spasticity and/or pain |
| 01/04/2006 | EP1610784A2 Forms of 5-azacytidine |
| 01/04/2006 | EP1610783A2 Modulation of cell death |
| 01/04/2006 | EP1610782A1 Antiviral combination of a dipyridodiazepinone and a further antiretroviral compound |
| 01/04/2006 | EP1610781A1 Antiviral combination of tipranavir and a further antiretroviral compound |
| 01/04/2006 | EP1610780A2 Cyclic protein tyrosine kinase inhibitors |
| 01/04/2006 | EP1610778A2 Treatment of benign prostatic hyperplasia |
| 01/04/2006 | EP1610777A1 Oral suspension of tegaserod |
| 01/04/2006 | EP1610776A2 Ophthalmic compositions for treating ocular hypertension |
| 01/04/2006 | EP1610775A2 Combination drug therapy for treating hypertension |
| 01/04/2006 | EP1610774A2 Tie-2 modulators and methods of use |
| 01/04/2006 | EP1610773A2 Use of compounds for the prevention of drug-induced cell toxicity |
| 01/04/2006 | EP1610772A2 Retinoid replacements and opsin agonists and methods for the use thereof |
| 01/04/2006 | EP1610771A2 Use of an alpha2-adrenoceptor antagonist for the treatment of epilepsy |
| 01/04/2006 | EP1610770A1 Use of an ibat inhibitor for the treatment of prophylaxis of constipation |
| 01/04/2006 | EP1610767A1 Morphine controlled release system |
| 01/04/2006 | EP1610764A1 Taste-masking vehicle for coated oxazolidinone particles |
| 01/04/2006 | EP1610763A2 Stable liposomes or micelles comprising a sphingolipid and a peg-lipopolymer |
| 01/04/2006 | EP1610761A2 Osmotic delivery system and method for decreasing start-up times for osmotic delivery systems |
| 01/04/2006 | EP1610760A2 Topical l-carnitine compositions |
| 01/04/2006 | EP1610759A2 Substituted quinobenzoxazine analogs |
| 01/04/2006 | EP1610753A2 Phenylenediamine urotensin-ii receptor antagonists and ccr-9 antagonists |
| 01/04/2006 | EP1610742A2 Methods and compositions for administration of trpv1 agonists |
| 01/04/2006 | EP1610738A1 Device for stimulating the female sexual organ, packaging and dispensing member |
| 01/04/2006 | EP1610614A2 Formulations for tyrosine kinase inhibitors |
| 01/04/2006 | EP1610613A2 Topical anthelmintic veterinary formulations |
| 01/04/2006 | EP1545225A4 Organic acids incorporated edible antimicrobial films |
| 01/04/2006 | EP1537132B1 Salt of morphine-6-glucuronide |
| 01/04/2006 | EP1536800B1 Synergistic interaction of abacavir and alovudine |
| 01/04/2006 | EP1494658B1 Natural phenolic products and derivatives thereof for protection against neurodegenerative diseases |
| 01/04/2006 | EP1434762A4 4'-methanesulfonyl-biphenyl derivatives as a highly selective cyclooxygenase-2 inhibitor |
| 01/04/2006 | EP1409455B1 Prostaglandin analogues-as ep4 receptor agonists |
| 01/04/2006 | EP1408030B1 Novel aliphatic compound, method of synthesis, and method of utilization |
| 01/04/2006 | EP1397153A4 Methods for protecting allogeneic islet transplant using soluble ctla4 mutant molecules |
| 01/04/2006 | EP1395585B1 Antibacterial agents |
| 01/04/2006 | EP1383741A4 Process for the preparation of benazepril |
| 01/04/2006 | EP1366082B1 Highly sulfated derivatives of k5 polysaccharide and their preparation |
| 01/04/2006 | EP1363873A4 Peptide deformylase inhibitors |